Short Interest in Affimed (NASDAQ:AFMD) Decreases By 39.5%

Affimed (NASDAQ:AFMD) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 611,400 shares, a decline of 39.5% from the November 15th total of 1,010,000 shares. Approximately 4.7% of the shares of the company are sold short. Based on an average daily volume of 180,400 shares, the short-interest ratio is presently 3.4 days.

Affimed Stock Down 3.5 %

Shares of Affimed stock opened at $2.18 on Friday. Affimed has a 52-week low of $2.02 and a 52-week high of $8.95. The company’s 50-day simple moving average is $3.10 and its 200-day simple moving average is $4.19. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Hedge Funds Weigh In On Affimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Choreo LLC acquired a new stake in shares of Affimed in the 2nd quarter valued at approximately $54,000. Point72 Asset Management L.P. lifted its holdings in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. Intellectus Partners LLC lifted its holdings in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 10,250 shares during the period. Jane Street Group LLC purchased a new stake in shares of Affimed during the 3rd quarter worth $44,000. Finally, FMR LLC grew its stake in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the period. Institutional investors and hedge funds own 30.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wells Fargo & Company decreased their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Affimed in a report on Tuesday. Stifel Nicolaus cut their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. According to MarketBeat, Affimed has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.